



ASX ANNOUNCEMENT

8 February 2021

Pharmacy Catalyst Members to support wheezo Sales with In-Pharmacy Asthma Management Program

RespiRI Limited (ASX:RSH) (“RespiRI” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce an agreement for the Pharmacy Catalyst members to range and sell wheezo™ in preparation for the implementation of the in-pharmacy asthma patient/wheezo program due to commence in March. The program will see pharmacists working with asthma sufferers to review their conditions, making any necessary recommendations including the inclusion of wheezo and the App where appropriate to improve patient management.

Pharmacy Catalyst are a member of Pharmacy Platform Pty Ltd, a recently formed entity combining the Advantage Group & Instigo. Providing its more than 350 members with services including professional service and education programs, Pharmacy Catalyst is committed to community engagement and a patient-centric focus. In December 2020, RespiRI announced a supply agreement with Pharmacy Platform for wheezo and the development of an in-pharmacy asthma clinical program. RespiRI is pleased that the first such program with Pharmacy Catalyst, supported by Cipla and the RespiRI Connect Care nursing team will commence as planned next month across Australia. Further the program will continue to be rolled out across other member pharmacies and white label options to other major pharmacy banner groups where Pharmacy Platform has active relationships throughout 2021.

Managing Director and Pharmacy Platform Board member, Michael Flannery said “The foundation of every pharmacy should be a deep understanding of their customer and being able to provide relevant and timely advice and support. With wheezo, our pharmacy members can provide much needed support to asthma patients and their caregivers with the objective of improving asthma management and outcomes as clearly there are still significant asthma patient management issues when the patient leave the care of their health care professional and we believe that this partnership with RespiRI will help address this.”

“Having Pharmacy Catalyst with their focus on individualised patient support is terrific for asthma patients and their caregivers and with wheezo now available, patients and caregivers can benefit from improved asthma management. The RespiRI team look forward to work with Pharmacy Catalyst members with programs that assist with patient engagement and education,” said RespiRI CEO and Managing Director, Mr Marjan Mikel.

Since Q4 CY2020, RespiRI has onboarded three pharmacy banner groups and a number of independent stores with a total network of 500 pharmacies across Australia. This represents an implied market footprint of approximately 10% based on the total number of ex-hospital community pharmacies across the country.

The Company remains in active discussions with several additional pharmacy banner groups, representing a pharmacy footprint of over 1,000 stores across Australia. The Company expects to make further ASX announcements once these discussions are finalised and initial orders have commenced.

Pharmacists are a trusted advisor for patients and on average, everyday 14 patients will discuss their asthma management with their pharmacist across the country. Poorly controlled asthma remains a significant problem in Australia with 1 in 10 asthma sufferers being admitted into hospital at least once a year due to asthma attacks and still today, 300 Australians die of asthma attack complications. It is hoped that this pharmacy led patient initiative will have a positive impact on these health outcomes and improve the quality of life on patients with asthma.

For further information about wheezo, follow the online link <https://wheezo.com>

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

™ wheezo is a trademark of Respiri Limited.

This ASX announcement dated 8 February 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and

prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respire only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respire will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.